LENZ THERAPEUTICS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
LENZ THERAPEUTICS, INC. (LENZ) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-09-30 was $0.00.
- LENZ THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-06-30 was $0.00.
- LENZ THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-03-31 was $0.00.
- LENZ THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-03-31 was $0.00.
- LENZ THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |